Verve Therapeutics

Verve Therapeutics is a biotechnology company committed to developing single-course gene editing medicines that can permanently lower blood lipid levels and reduce the risk of cardiovascular disease. Their approach leverages advancements in gene editing technology, particularly base editing, to target specific genes implicated in elevated cholesterol levels, such as PCSK9 and ANGPTL3. This approach aims to disrupt the current chronic care model for managing cardiovascular disease by offering a potentially life-long solution with a single treatment.

Verve is advancing a pipeline of gene editing programs focused initially on individuals with familial hypercholesterolemia, a genetic condition leading to high cholesterol levels. They plan to expand their focus to broader populations with established cardiovascular disease and ultimately, to individuals at risk for cardiovascular disease in the general population. Verve's commitment to patient-centricity and ethical development is evident in their collaboration with medical professionals, commitment to transparency, and pursuit of rigorous safety protocols.

Verve Therapeutics offers a comprehensive benefits package designed to support employee well-being and financial security. These include generous paid time off, comprehensive health insurance, life and disability insurance, employer HSA contributions, paid parental leave, a 401(k) with company match, subsidized transportation and parking, a financial wellbeing program, a cell phone stipend, tuition reimbursement, professional development programs, wellness days, an employee assistance program, a lifestyle spending account, and office perks such as snacks, coffee, and company-provided lunch.

Verve Therapeutics is a biotechnology company dedicated to protecting the world from cardiovascular disease (CVD) by developing single-course gene editing medicines. They are leveraging advances in gene editing technology to address the root causes of CVD, specifically focusing on lowering LDL-C levels and disrupting the chronic care model that often fails to provide adequate care for patients. By permanently inactivating specific genes in the liver that contribute to ASCVD risk, Verve aims to offer a life-changing treatment option that significantly reduces the burden of this global health epidemic.

Verve Therapeutics cultivates a collaborative and caring environment that values grit, spirit, drive, and passion. They are committed to providing a supportive and inclusive workplace that recognizes the importance of work-life balance and employee well-being. The company encourages teamwork, celebrates individual contributions, and promotes a culture of transparency and open communication.

Verve Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace. The company values a culture where all employees feel respected, valued, and empowered to contribute their unique perspectives. They are actively working to create an environment where everyone can thrive, regardless of their background, identity, or experiences. Verve recognizes that diversity strengthens their team, enhances creativity, and fosters innovation, ultimately benefiting their work to develop groundbreaking gene editing medicines for cardiovascular disease.